Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4-Reference-Cited by-全球学者库

Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4

Published:2017-05-08 Issue:6 Volume:23 Page:742-752
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Zhao Guang-Nian,Zhang Peng,Gong Jun,Zhang Xiao-Jing,Wang Pi-Xiao,Yin Miao,Jiang Zhou,Shen Li-Jun,Ji Yan-Xiao,Tong Jingjing,Wang Yutao,Wei Qiao-Fang,Wang Yong,Zhu Xue-Yong,Zhang Xin,Fang Jing,Xie Qingguo,She Zhi-Gang,Wang Zhihua,Huang Zan,Li Hongliang

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.4334.pdf

Reference78 articles.

1. Wree, A., Broderick, L., Canbay, A., Hoffman, H.M. & Feldstein, A.E. From NAFLD to NASH to cirrhosis—new insights into disease mechanisms. Nat. Rev. Gastroenterol. Hepatol. 10, 627–636 (2013).

2. Younossi, Z.M. et al. Global epidemiology of non-alcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence and outcomes. Hepatology 64, 73–84 (2016).

3. Cohen, J.C., Horton, J.D. & Hobbs, H.H. Human fatty liver disease: old questions and new insights. Science 332, 1519–1523 (2011).

4. Byrne, C.D. & Targher, G. NAFLD: a multisystem disease. J. Hepatol. 62 (Suppl. 1), S47–S64 (2015).

5. LaBrecque, D.R. et al. World Gastroenterology Organization global guidelines: non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. J. Clin. Gastroenterol. 48, 467–473 (2014).

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies;Molecular Aspects of Medicine;2024-02

2. Nuclear miR-204-3p mitigates metabolic dysfunction-associated steatotic liver disease in mice;Journal of Hepatology;2024-02

3. Direct degradation and stabilization of proteins: New horizons in treatment of nonalcoholic steatohepatitis;Biochemical Pharmacology;2024-02

4. A red-emission and viscosity-ultrasensitive probe for identifying non-alcoholic fatty liver via imaging lysosomal viscosity;Sensors and Actuators B: Chemical;2024-01

5. ESCRT-III Component CHMP4C Attenuates Cardiac Hypertrophy by Targeting the Endo-Lysosomal Degradation of EGFR;Hypertension;2023-12